370 likes | 561 Views
Spotlight on Emerging Agents for Myeloproliferative Neoplasms. Myeloproliferative Neoplasms (MPNs). Main Goal in PV Therapy: Control Thrombotic Events. Management of High-Risk PV. ET -- Current Therapy. MF – Current Treatment. Unmet Needs in MPNs. Novel Agents in Development.
E N D
Spotlight on Emerging Agents for Myeloproliferative Neoplasms
JAKARTA: Fedratinib (SAR302503) Phase 3 Study in Intermediate-2 or High-Risk MF
JAKARTA: Spleen Volume Response, Primary Endpoint, Primary and Secondary Analyses, ITT
JAKARTA-2: Single-Arm, Multicenter, Open-Label Study (NCT01523171)[a]